Please assess the completion status of the following clinical trial:

Trial Title: Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Taking at least three medications for blood pressure (one a diuretic)~* Uncontrolled high blood pressure~* Abnormal kidney function (with-eGFR, a measure of kidney function, of 25 - ≤ 45 mL/min/1.73m2~* Normal Blood serum Potassium in a specific range (4.3 - 5.1 mEq/L)~Exclusion Criteria:~* History of untreated known causes of high blood pressure, excluding kidney disease (not CKD)~* Inability to measure BP~* Not taking high blood pressure medications as prescribed medications~* Recent change in renal function (in the past 3 months) which has required hospitalization or dialysis~* Renal transplant~* History of cancer within past 12 months~* Recent cardiovascular event with last 3 months~* Clinically significant abnormalities of heart rhythm (ventricular arrhythmia or atrial fibrillation with uncontrolled heart rate)~* Inability to take study medication~* Alcoholism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 - Patiromer (Type: EXPERIMENTAL): spironolactone + blinded patiromer
- Group 2 - Placebo (Type: EXPERIMENTAL): spironolactone + blinded placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).